Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Expected to Announce Quarterly Sales of $522.89 Million
Wall Street analysts expect Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) to report $522.89 million in sales for the current fiscal quarter, according to Zacks. Eight analysts have issued estimates for Jazz Pharmaceuticals’ earnings. The lowest sales estimate is $515.40 million and the highest is $530.00 million. Jazz Pharmaceuticals reported sales of $469.37 million during the same quarter last year, which indicates a positive year-over-year growth rate of 11.4%. The firm is expected to issue its next earnings results on Tuesday, November 5th.
According to Zacks, analysts expect that Jazz Pharmaceuticals will report full year sales of $2.11 billion for the current year, with estimates ranging from $2.09 billion to $2.15 billion. For the next financial year, analysts anticipate that the company will report sales of $2.32 billion, with estimates ranging from $2.22 billion to $2.39 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that that provide coverage for Jazz Pharmaceuticals.
Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings data on Tuesday, August 6th. The specialty pharmaceutical company reported $3.65 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.16 by $0.49. The firm had revenue of $534.13 million during the quarter, compared to analyst estimates of $507.23 million. Jazz Pharmaceuticals had a net margin of 32.99% and a return on equity of 27.72%. The business’s quarterly revenue was up 6.7% on a year-over-year basis. During the same period in the previous year, the business posted $3.49 EPS.
Shares of JAZZ traded up $0.92 during mid-day trading on Monday, reaching $135.75. The company’s stock had a trading volume of 357,873 shares, compared to its average volume of 567,082. The stock has a market cap of $7.69 billion, a PE ratio of 11.09, a P/E/G ratio of 1.08 and a beta of 1.14. The company has a current ratio of 3.71, a quick ratio of 3.52 and a debt-to-equity ratio of 0.58. Jazz Pharmaceuticals has a 52 week low of $113.52 and a 52 week high of $176.73. The company’s fifty day moving average price is $137.73 and its two-hundred day moving average price is $134.55.
In other Jazz Pharmaceuticals news, Director Catherine A. Sohn sold 726 shares of the business’s stock in a transaction on Friday, August 9th. The shares were sold at an average price of $135.65, for a total transaction of $98,481.90. Following the transaction, the director now directly owns 9,574 shares of the company’s stock, valued at approximately $1,298,713.10. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, SVP Paul Treacy sold 4,371 shares of the business’s stock in a transaction on Monday, August 12th. The shares were sold at an average price of $137.40, for a total transaction of $600,575.40. The disclosure for this sale can be found here. 4.30% of the stock is currently owned by insiders.
A number of institutional investors have recently modified their holdings of the business. Signaturefd LLC increased its position in Jazz Pharmaceuticals by 56.3% during the 2nd quarter. Signaturefd LLC now owns 200 shares of the specialty pharmaceutical company’s stock valued at $29,000 after purchasing an additional 72 shares during the period. Commonwealth Equity Services LLC increased its position in Jazz Pharmaceuticals by 2.8% during the 2nd quarter. Commonwealth Equity Services LLC now owns 3,338 shares of the specialty pharmaceutical company’s stock valued at $475,000 after purchasing an additional 92 shares during the period. MAI Capital Management increased its position in Jazz Pharmaceuticals by 2.2% during the 2nd quarter. MAI Capital Management now owns 4,364 shares of the specialty pharmaceutical company’s stock valued at $622,000 after purchasing an additional 96 shares during the period. MML Investors Services LLC increased its position in Jazz Pharmaceuticals by 4.4% during the 2nd quarter. MML Investors Services LLC now owns 2,593 shares of the specialty pharmaceutical company’s stock valued at $370,000 after purchasing an additional 109 shares during the period. Finally, Confluence Investment Management LLC increased its position in Jazz Pharmaceuticals by 2.9% during the 2nd quarter. Confluence Investment Management LLC now owns 4,243 shares of the specialty pharmaceutical company’s stock valued at $605,000 after purchasing an additional 118 shares during the period. 90.30% of the stock is currently owned by institutional investors and hedge funds.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.
Read More: What is the operating income formula?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.